IMVT

Immunovant Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth 0/10
  • Value 6/10
Immunovant sales and earnings growth
IMVT Growth
Low
  • Revenue Y/Y 0.00%
  • EPS Y/Y -1.47%
  • FCF Y/Y -8.15%
Immunovant gross and profit margin trends
IMVT Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y 4641.80%
Immunovant net debt vs free cash flow
IMVT Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage NA

Immunovant stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks